The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
Background. The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis. Methods. A retrospective single-center study based on a Chinese population...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2022/6562149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554789758566400 |
|---|---|
| author | Ziheng Ye Xiaotian Xia Peipei Xu Wenfei Liu Shoufei Wang Youben Fan Minggao Guo |
| author_facet | Ziheng Ye Xiaotian Xia Peipei Xu Wenfei Liu Shoufei Wang Youben Fan Minggao Guo |
| author_sort | Ziheng Ye |
| collection | DOAJ |
| description | Background. The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis. Methods. A retrospective single-center study based on a Chinese population was performed to analyze the association of the BRAF V600E mutation with several clinicopathological features. Kaplan–Meier survival curves and Cox proportional hazards regression analysis were applied to implement the survival analysis. Results. The BRAF V600E mutation was present in 1102 (87.7%) of the 1257 patients and was significantly associated with older age, conventional subtype, multifocality, advanced TNM stage, and a reduced prevalence of Hashimoto’s thyroiditis. The Kaplan–Meier survival curves demonstrated that the difference between the BRAF V600E-positive and BRAF V600E-negative groups was significant with a log-rank P-value of 0.048. The Cox proportional hazards regression analysis adjusted HR was 3.731 (95% CI, 1.457 to 9.554). We further demonstrated that larger tumor size (>1 cm), extrathyroidal extension (ETE), and lateral lymph node metastasis (LNM) were associated with a higher probability of PTC recurrence in patients harboring the BRAF V600E mutation. Conclusions. The BRAF V600E mutation remains an independent risk factor for PTC recurrence and may be useful for clinical decisions when it combines with some pathological factors. |
| format | Article |
| id | doaj-art-7df13405127b4a58bd5611b96a021592 |
| institution | Kabale University |
| issn | 1687-8345 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-7df13405127b4a58bd5611b96a0215922025-02-03T05:50:31ZengWileyInternational Journal of Endocrinology1687-83452022-01-01202210.1155/2022/6562149The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese PopulationZiheng Ye0Xiaotian Xia1Peipei Xu2Wenfei Liu3Shoufei Wang4Youben Fan5Minggao Guo6Center of Thyroid and ParathyroidCenter of Thyroid and ParathyroidCenter of Thyroid and ParathyroidCenter of Thyroid and ParathyroidCenter of Thyroid and ParathyroidCenter of Thyroid and ParathyroidCenter of Thyroid and ParathyroidBackground. The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis. Methods. A retrospective single-center study based on a Chinese population was performed to analyze the association of the BRAF V600E mutation with several clinicopathological features. Kaplan–Meier survival curves and Cox proportional hazards regression analysis were applied to implement the survival analysis. Results. The BRAF V600E mutation was present in 1102 (87.7%) of the 1257 patients and was significantly associated with older age, conventional subtype, multifocality, advanced TNM stage, and a reduced prevalence of Hashimoto’s thyroiditis. The Kaplan–Meier survival curves demonstrated that the difference between the BRAF V600E-positive and BRAF V600E-negative groups was significant with a log-rank P-value of 0.048. The Cox proportional hazards regression analysis adjusted HR was 3.731 (95% CI, 1.457 to 9.554). We further demonstrated that larger tumor size (>1 cm), extrathyroidal extension (ETE), and lateral lymph node metastasis (LNM) were associated with a higher probability of PTC recurrence in patients harboring the BRAF V600E mutation. Conclusions. The BRAF V600E mutation remains an independent risk factor for PTC recurrence and may be useful for clinical decisions when it combines with some pathological factors.http://dx.doi.org/10.1155/2022/6562149 |
| spellingShingle | Ziheng Ye Xiaotian Xia Peipei Xu Wenfei Liu Shoufei Wang Youben Fan Minggao Guo The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population International Journal of Endocrinology |
| title | The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population |
| title_full | The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population |
| title_fullStr | The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population |
| title_full_unstemmed | The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population |
| title_short | The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population |
| title_sort | prognostic implication of the braf v600e mutation in papillary thyroid cancer in a chinese population |
| url | http://dx.doi.org/10.1155/2022/6562149 |
| work_keys_str_mv | AT zihengye theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT xiaotianxia theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT peipeixu theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT wenfeiliu theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT shoufeiwang theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT youbenfan theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT minggaoguo theprognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT zihengye prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT xiaotianxia prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT peipeixu prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT wenfeiliu prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT shoufeiwang prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT youbenfan prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation AT minggaoguo prognosticimplicationofthebrafv600emutationinpapillarythyroidcancerinachinesepopulation |